UBS AM
CDMO

UBS AM’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

UBS AM’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-124,978
Closed -$1.54M – 2724
2024
Q4 		$1.54M Sell
124,978
-14,465
-10% -$166K ﹤0.01% 2164
2024
Q3 		$1.59M Sell
139,443
-24,323
-15% -$244K ﹤0.01% 2161
2024
Q2 		$1.17M Buy
163,766
+103,435
+171% +$791K ﹤0.01% 2298
2024
Q1 		$404K Hold
60,331
– – ﹤0.01% 2341
2023
Q4 		$392K Hold
60,331
– – ﹤0.01% 2376
2023
Q3 		$570K Hold
60,331
– – ﹤0.01% 2246
2023
Q2 		$1.13M Hold
60,331
– – ﹤0.01% 1942
2023
Q1 		$1.13M Buy
60,331
+4,885
+9% +$80.2K ﹤0.01% 1942
2022
Q4 		$763K Hold
55,446
– – ﹤0.01% 1989
2022
Q3 		$1.06M Buy
55,446
+474
+0.9% +$8.64K ﹤0.01% 1935
2022
Q2 		$839K Sell
54,972
-1,647
-3% -$24.4K ﹤0.01% 2063
2022
Q1 		$1.15M Hold
56,619
– – ﹤0.01% 2064
2021
Q4 		$1.65M Hold
56,619
– – ﹤0.01% 1963
2021
Q3 		$1.22M Buy
56,619
+6,218
+12% +$150K ﹤0.01% 2057
2021
Q2 		$1.29M Buy
+50,401
New +$1.08M ﹤0.01% 2062

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS AM's CDMO Position: Q1 2025 in Review

UBS AM sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 124,978 shares — an estimated $1.54M sold.

UBS AM first reported a position in CDMO in Q2 2021 and held it in 15 quarters. The position peaked at $1.65M in Q4 2021. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • UBS AM reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS AM sold 124,978 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $1.54M.
  • UBS AM first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
  • UBS AM's Avid Bioservices, Inc. Common Stock position peaked at $1.65M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.